Pancreatic Cancer Research

ResearcherOkayama UniversityActive in the last 2 years

Daisuke Uchida

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2809-2707; OpenAlex author ID A5070518281. Sources: OpenAlex.

Their work

Papers
11
Trials
0
Grants
0
Labs led
0
Collaborators
23
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: 2 papers · 2017: 1 paper · 2018: 1 paper · 2019: 2 papers · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper

Papers 11

  1. Clinical Significance of a Cell-Of-Origin-Based Classification in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1111/cas.70533↗
  2. Cysts or necrotic components in pancreatic ductal adenocarcinoma is associated with the risk of EUS-FNA/B complications including needle tract seeding. Co-author DOI 10.1016/j.pan.2023.10.018↗
  3. Plasma KRAS mutations predict the early recurrence after surgical resection of pancreatic cancer. Co-author DOI 10.1080/15384047.2021.1980312↗
  4. Evaluation of Local Recurrence of Pancreatic Cancer by KRAS Mutation Analysis Using Washes from Endoscopic Ultrasound-Guided Fine-Needle Aspiration. Co-author DOI 10.1007/s10620-019-06006-6↗
  5. Utility of liquid biopsy using urine in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1080/15384047.2019.1638685↗
  6. Diagnostic Ability of Convex-Arrayed Endoscopic Ultrasonography for Major Vascular Invasion in Pancreatic Cancer. Co-author DOI 10.5946/ce.2018.163↗
  7. Efficacy and safety of chemotherapy after endoscopic double stenting for malignant duodenal and biliary obstructions in patients with advanced pancreatic cance… Co-author DOI 10.1186/s12876-018-0886-8↗
  8. Utility of serum DNA as a marker for KRAS mutations in pancreatic cancer tissue. Co-author DOI 10.1016/j.pan.2016.12.011↗
  9. Novel REIC/Dkk-3-encoding adenoviral vector as a promising therapeutic agent for pancreatic cancer. Co-author DOI 10.1038/cgt.2016.31↗
  10. Synergistic anti-pancreatic cancer immunological effects by treatment with reduced expression in immortalized cells/dickkopf-3 protein and peripheral blood mon… Co-author DOI 10.1111/jgh.13259↗
  11. Potential of adenovirus-mediated REIC/Dkk-3 gene therapy for use in the treatment of pancreatic cancer. Co-author DOI 10.1111/jgh.12501↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shigeru Horiguchi · 11 shared papers, 2014–2026 · strength 1.01
  2. Hironari Kato · 10 shared papers, 2014–2023 · strength 0.79
  3. Kazuyuki Matsumoto · 7 shared papers, 2017–2023 · strength 0.65
  4. Soichiro Ako · 5 shared papers, 2017–2026 · strength 0.57
  5. Hideaki Kinugasa · 5 shared papers, 2017–2026 · strength 0.57
  6. Hiroyuki Terasawa · 4 shared papers, 2019–2026 · strength 0.55
  7. Koichiro Tsutsumi · 4 shared papers, 2017–2026 · strength 0.50
  8. Kazuhiro Nouso · 7 shared papers, 2014–2021 · strength 0.48
  9. Yuki Fujii · 3 shared papers, 2019–2026 · strength 0.45
  10. Shinichiro Muro · 5 shared papers, 2017–2021 · strength 0.42
  11. Tatsuya Kikuchi · 2 shared papers, 2023–2026 · strength 0.36
  12. Motoyuki Otsuka · 2 shared papers, 2023–2026 · strength 0.36
  13. Hiroyuki Okada · 3 shared papers, 2019–2020 · strength 0.27
  14. Kazuya Yasui · 1 shared paper, 2026 · strength 0.22
  15. Kosei Takagi · 1 shared paper, 2026 · strength 0.22
  16. Hiroyuki Okada · 2 shared papers, 2018–2021 · strength 0.18
  17. Yuzo Umeda · 1 shared paper, 2021 · strength 0.10
  18. Ryuichi Yoshida · 1 shared paper, 2021 · strength 0.10
  19. Hiroaki Sawahara · 2 shared papers, 2016 · strength 0.10
  20. Kazuhide Yamamoto · 2 shared papers, 2014–2016 · strength 0.09
  21. Hiroyuki M. OKADA · 1 shared paper, 2017 · strength 0.06
  22. Masakiyo Sakaguchi · 1 shared paper, 2016 · strength 0.05
  23. H Okada · 1 shared paper, 2016 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.